GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ironwood Pharmaceuticals Inc (NAS:IRWD) » Definitions » E10

Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) E10 : $-0.80 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Ironwood Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Ironwood Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.010. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.80 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 5.20% per year. During the past 5 years, the average E10 Growth Rate was 20.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Ironwood Pharmaceuticals was 35.40% per year. The lowest was 5.20% per year. And the median was 25.10% per year.

As of today (2024-04-27), Ironwood Pharmaceuticals's current stock price is $7.82. Ironwood Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $-0.80. Ironwood Pharmaceuticals's Shiller PE Ratio of today is .


Ironwood Pharmaceuticals E10 Historical Data

The historical data trend for Ironwood Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ironwood Pharmaceuticals E10 Chart

Ironwood Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.07 -0.94 -0.60 -0.45 -0.80

Ironwood Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.45 -0.32 -0.93 -0.86 -0.80

Competitive Comparison of Ironwood Pharmaceuticals's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ironwood Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ironwood Pharmaceuticals's Shiller PE Ratio falls into.



Ironwood Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ironwood Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.01/129.4194*129.4194
=-0.010

Current CPI (Dec. 2023) = 129.4194.

Ironwood Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201403 -0.380 99.695 -0.493
201406 -0.440 100.560 -0.566
201409 -0.300 100.428 -0.387
201412 -0.270 99.070 -0.353
201503 -0.240 99.621 -0.312
201506 -0.340 100.684 -0.437
201509 -0.330 100.392 -0.425
201512 -0.090 99.792 -0.117
201603 -0.090 100.470 -0.116
201606 -0.150 101.688 -0.191
201609 -0.230 101.861 -0.292
201612 -0.090 101.863 -0.114
201703 -0.360 102.862 -0.453
201706 -0.300 103.349 -0.376
201709 -0.220 104.136 -0.273
201712 0.080 104.011 0.100
201803 -0.290 105.290 -0.356
201806 -0.320 106.317 -0.390
201809 -1.140 106.507 -1.385
201812 -0.100 105.998 -0.122
201903 -0.380 107.251 -0.459
201906 0.080 108.070 0.096
201909 0.130 108.329 0.155
201912 0.300 108.420 0.358
202003 0.020 108.902 0.024
202006 0.160 108.767 0.190
202009 0.210 109.815 0.247
202012 0.270 109.897 0.318
202103 0.250 111.754 0.290
202106 2.390 114.631 2.698
202109 0.340 115.734 0.380
202112 0.250 117.630 0.275
202203 0.210 121.301 0.224
202206 0.210 125.017 0.217
202209 0.280 125.227 0.289
202212 0.270 125.222 0.279
202303 0.250 127.348 0.254
202306 -6.840 128.729 -6.877
202309 0.090 129.860 0.090
202312 -0.010 129.419 -0.010

Add all the adjusted EPS together and divide 10 will get our e10.


Ironwood Pharmaceuticals  (NAS:IRWD) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Ironwood Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Ironwood Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
100 Summer Street, Suite 2300, Boston, MA, USA, 02110
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Executives
Marla L Kessler director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Andrew Davis officer: SVP, Chief Business Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sravan Kumar Emany officer: SVP, Chief Financial Officer 100 SUMMER ST, SUITE 2300, BOSTON MA 02109
Ronald Silver officer: Principal Accounting Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Minardo John officer: Chief Legal Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Thomas A Mccourt officer: Chief Commercial Officer C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Michael Shetzline officer: CMO,SVP,Head-Res&Drug 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jason Rickard officer: SVP, Chief Operating Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Mark G Currie officer: Chief Scientific Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Edward P Owens director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Gina Consylman officer: Chief Accounting Officer C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Kilroy Conor officer: SVP, GC & Secretary 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110